Tempus AI's growth and partnerships make it an attractive investment. See why TEM stock is a solid Buy due to its ...

We recently compiled a list of the 10 AI News You Shouldn’t Miss. In this article, we are going to take a look at where ...

Piper Sandler analyst David Westenberg raised the firm’s price target on Tempus AI (TEM) to $70 from $40 and keeps a Neutral rating on ...

Fintel reports that on November 11, 2024, Stifel downgraded their outlook for Tempus AI (NasdaqGS:TEM) from Buy to Hold. ...

Aliso Viejo-based Ambry Genetics Corp. on Nov. 4 announced an agreement to be acquired for $600 million by Tempus AI Inc.

With Ambry Genetics in tow, Eric Lefkofsky's biotech startup hopes to accelerate its drive toward turning a profit.

Stifel Nicolaus analyst Daniel Arias downgraded the rating on Tempus AI, Inc. Class A (TEM – Research Report) to a Hold yesterday, ...

After a quarter century as a serial entrepreneur, Eric Lefkofsky wants his latest unicorn, health tech firm Tempus AI, to be the “enduring legacy” of his career. Here’s how he hopes it will ...

CEO Eric Lefkofsky said the purchase of Ambry Genetics will expand Tempus’ testing portfolio and bring in a fast-growing ...

In addition, please check the fund’s top five holdings to know its best picks in 2024. Baron Discovery Fund highlighted ...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the ...

Tempus AI said it agreed to pay $375 million in cash and $225 million in shares to acquire genetic testing company Ambry Genetics. Ambry conducts hereditary cancer screening and currently serves as ...